CN107233563A - Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus, preparation, using and preparation method thereof - Google Patents
Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus, preparation, using and preparation method thereof Download PDFInfo
- Publication number
- CN107233563A CN107233563A CN201710557511.7A CN201710557511A CN107233563A CN 107233563 A CN107233563 A CN 107233563A CN 201710557511 A CN201710557511 A CN 201710557511A CN 107233563 A CN107233563 A CN 107233563A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicinal composition
- tibetan medicinal
- highland barley
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 133
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 90
- 235000007340 Hordeum vulgare Nutrition 0.000 title claims abstract description 70
- 241000228347 Monascus <ascomycete fungus> Species 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 240000005979 Hordeum vulgare Species 0.000 title 1
- 241000209219 Hordeum Species 0.000 claims abstract description 69
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000011575 calcium Substances 0.000 claims abstract description 48
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 48
- 239000000284 extract Substances 0.000 claims abstract description 30
- 239000002994 raw material Substances 0.000 claims abstract description 30
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 23
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 23
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 23
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 23
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 23
- 239000011710 vitamin D Substances 0.000 claims abstract description 23
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 23
- 229940046008 vitamin d Drugs 0.000 claims abstract description 23
- 235000018905 epimedium Nutrition 0.000 claims abstract description 22
- 241000893536 Epimedium Species 0.000 claims abstract description 20
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 18
- YCHKFNUDARWTSK-FRWAFGSFSA-M potassium;(3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid;chloride Chemical class [Cl-].[K+].OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O YCHKFNUDARWTSK-FRWAFGSFSA-M 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 10
- 238000000638 solvent extraction Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000006187 pill Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 4
- 239000001354 calcium citrate Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- -1 patch Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 241001016310 Epimedium grandiflorum Species 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 239000005018 casein Substances 0.000 claims description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 claims 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 1
- UUVBYOGFRMMMQL-UHFFFAOYSA-N calcium;phosphoric acid Chemical compound [Ca].OP(O)(O)=O UUVBYOGFRMMMQL-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- FGNPLIQZJCYWLE-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid Chemical compound OS(O)(=O)=O.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO FGNPLIQZJCYWLE-BTVCFUMJSA-N 0.000 abstract description 2
- DKHJWWRYTONYHB-UHFFFAOYSA-N CPP Chemical compound OC(=O)C(C)OC1=CC=C(Cl)C=C1 DKHJWWRYTONYHB-UHFFFAOYSA-N 0.000 description 20
- 239000005025 cast polypropylene Substances 0.000 description 20
- 208000001132 Osteoporosis Diseases 0.000 description 19
- 239000002671 adjuvant Substances 0.000 description 13
- 230000002265 prevention Effects 0.000 description 13
- 210000000813 small intestine Anatomy 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 210000000845 cartilage Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010017076 Fracture Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000037182 bone density Effects 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 229920002567 Chondroitin Polymers 0.000 description 3
- 229910052785 arsenic Inorganic materials 0.000 description 3
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 241001148782 Davallia Species 0.000 description 2
- 206010013700 Drug hypersensitivity Diseases 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000009056 active transport Effects 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 201000005311 drug allergy Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000004072 osteoblast differentiation Effects 0.000 description 2
- 230000001599 osteoclastic effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000017375 Scheuermann Disease Diseases 0.000 description 1
- 101000794475 Schistosoma mansoni Calcium-binding protein Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- POIARNZEYGURDG-FNORWQNLSA-N beta-damascenone Chemical compound C\C=C\C(=O)C1=C(C)C=CCC1(C)C POIARNZEYGURDG-FNORWQNLSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 102000014823 calbindin Human genes 0.000 description 1
- 108060001061 calbindin Proteins 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention disclose a kind of Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus, preparation, using and preparation method thereof, in parts by weight, the Tibetan medicinal composition raw material includes：15~45 parts of highland barley monascus, 10~30 parts of Yak Bone, 10~20 parts of Rhizoma Drynariae extract, 5~15 parts of Shorthorned Epimedium P.E, 1~10 part of calcium agent, 1~10 part of D Glucosamine sulfate potassium chlorides, 1~10 part of chondroitin sulfate, 1~10 part of CPP, 1~10 part of vitamin D；The pre- preventing bone rarefaction remarkable result of Tibetan medicinal composition and its preparation, has no toxic side effect to human body.
Description
Technical field
The present invention relates to field of pharmacology, and in particular to a kind of Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus,
Preparation, using and preparation method thereof.
Background technology
Osteoporosis be in, the elderly's common disease, frequently-occurring disease, have a strong impact on the Health and Living quality of such crowd,
Osteoporosis and its caused fracture occupy the 7th in current common disease, in seriously threaten, the health of the elderly,
Make the public health problem in the whole world.Osteoporosis is reduced with bone amount, including bone mineral and matrix equal proportion
Reduce, bone tissue microstructure is degenerated and is characterized, show as trabecular bone structure destruction, attenuate and be broken, and then cause the crisp of bone
Property increase, biomechanics of bone intensity decline, load endurance reduction, it is prone to capillary fracture or a kind of systemic bone of complete fracture
Bone disease.
It is many at present using replenishing the calcium, sex hormone, calcitonin, diphosphonate and fluoride etc. be used for clinical treatment, though have certain
Curative effect, but side effect is big.Simple replenishing the calcium is only capable of delaying but can not prevent the loss of bone amount.
The content of the invention
In view of this, this application provides a kind of Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus, preparation, application
And preparation method thereof；The pre- preventing bone rarefaction remarkable result of Tibetan medicinal composition and its preparation, has no toxic side effect to human body.
To solve above technical problem, the technical scheme that the present invention is provided is a kind of pre- preventing bone rarefaction containing highland barley monascus
Tibetan medicinal composition, in parts by weight, the Tibetan medicinal composition raw material include：15~45 parts of highland barley monascus, 10~30 parts of Yak Bone,
10~20 parts of Rhizoma Drynariae extract, 5~15 parts of Shorthorned Epimedium P.E, 1~10 part of calcium agent, D- Glucosamine sulfate potassium chlorides 1~
10 parts, 1~10 part of chondroitin sulfate, 1~10 part of CPP, 1~10 part of vitamin D.
It is preferred that, in parts by weight, the Tibetan medicinal composition raw material includes：25~40 parts of highland barley monascus, Yak Bone 15~
25 parts, 12~18 parts of Rhizoma Drynariae extract, 7~13 parts of Shorthorned Epimedium P.E, 2~8 parts of calcium agent, D- Glucosamine sulfate potassium chlorides
2~8 parts, 2~8 parts of chondroitin sulfate, 2~8 parts of CPP, 2~8 parts of vitamin D.
It is preferred that, in parts by weight, the Tibetan medicinal composition raw material includes：30 parts of highland barley monascus, 20 parts of Yak Bone, bone are broken
Mend 15 parts of extract, 10 parts of Shorthorned Epimedium P.E, 5 parts of calcium agent, 5 parts of D- Glucosamine sulfate potassium chlorides, 5 parts of chondroitin sulfate,
5 parts of CPP, 5 parts of vitamin D.
It is preferred that, the calcium agent is calcium carbonate, calcium citrate, calcium phosphate.
It is preferred that, the calcium agent calcium carbonate.
Present invention also offers a kind of Tibetan medicinal composition preparation of pre- preventing bone rarefaction containing highland barley monascus, the Tibetan medicine combination
Thing preparation is made up of above-mentioned Tibetan medicinal composition and pharmaceutically acceptable auxiliary material.
It is preferred that, the preparation formulation is solution, syrup, granule, capsule, powder, pill, tablet, lyophilized
Pulvis, patch, gel, film, vina or extract.
It is preferred that, it is calculated in mass percent, Tibetan medicinal composition content range described in the preparation is 50%~90%.
It is preferred that, it is calculated in mass percent, Tibetan medicinal composition content range described in the preparation is 70%.
Present invention also offers application of the above-mentioned Tibetan medicinal composition in the health food of pre- preventing bone rarefaction.
Present invention also offers a kind of preparation method of Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus, including with
Lower step：In parts by weight, the composition material includes：15~45 parts of highland barley monascus, 10~30 parts of Yak Bone, the rhizome of davallia are carried
Take 10~20 parts of thing, 5~15 parts of Shorthorned Epimedium P.E, 1~10 part of calcium agent, 1~10 part of D- Glucosamine sulfate potassium chlorides, sulfuric acid
1~10 part of chondroitin, 1~10 part of CPP, 1~10 part of vitamin D；After the raw material is crushed, solvent extraction,
Filtrate is collected, concentration is produced.
It is preferred that, the solvent is water or ethanol.
It is preferred that, the solvent is water or ethanol.
It is preferred that, the ethanol is 50~75vol% ethanol.
It is preferred that, the solvent extraction temperature is 75~100 DEG C.
It is preferred that, the solvent extraction time is 1~3h.
It is preferred that, the raw material is 1 with the solvent volume ratio：(5~10).
It is preferred that, the concentration is specially to be concentrated into density for 0.4~0.6g/mL.
Part described in technical solution of the present invention is in gram.
Natural statin substance content is high in highland barley monascus, and statin substance can promote bone cell proliferation, can increase bone close
Degree, the microstructure for repairing bone.
Rhizoma Drynariae extract can promote the osteogenic of mesenchymal stem cells MSCs to break up, moreover it is possible to promote the increasing of Gegenbaur's cell
Grow ripe with calcification, also have certain inhibitory action to osteoclastic bone resorption, can play improves the work of osteoporosis symptoms
With.
Shorthorned Epimedium P.E has the synthesis for promoting bone marrow cell DNA, promotes energy of the MSCs to osteoblast differentiation
Power.
Bone collagen is rich in Yak Bone marrow, deposition of the inanimate matters such as calcium, phosphorus on bone can be promoted, thus can be played
Repair the effect of gelatine basic stitch.
D- aminoglucose sulfates are a kind of derivatives of native amino monose, are synthetic proteins glycan in cartilage matrix
Necessary important component.Proteoglycans can make articular cartilage that there is absorption to impact by suppressing the tensile force of collagenous fibres
The function of power.Meanwhile, D- aminoglucose sulfates play direct antiinflammatory action, can relief from osteoarthritis pain symptom, change
Kind function of joint.
Chondroitin sulfate is the glutinous polysaccharose substance for being extracted from animal cartilage, in angiocardiopathy, preventing and treating of arthropathy etc.
Aspect has important effect, and chondroitin sulfate can provide pad effect, relax the impact and friction during action；It is used as delivery pipe
Road, chondroitin sulfate is that the important oxygen of cartilage conveying is supplied and nutrient, while carbon dioxide and waste are excluded.Other sulphur
Aching and limp ossein may also suppress the ferment of destruction cartilage, in case cartilage is decomposed or dissolved.
CPP is using bovine casein as raw material, by many with bioactivity made from biotechnology
Peptide, can effectively facilitate absorption and utilization of the human body to the divalent mineral nutrient such as calcium, iron, zinc.
Vitamin D is sterol analog derivative, can control and adjust the absorption of calcium with smoothly, adjust again in Bone m etabolism
Medicine body liquid should be, and osteoclast and osteoblast differentiation and propagation are all adjusted by vitamin D.
Calcium is the main component of bone, and the intake of calcium influences the nutritional status of bone.Calcium agent includes inorganic calcium and organic
Sour calcium, it is also one of method for replenishing the calcium to take calcium agent.
One of critical function of chondroitin is exactly, as conveyance conduit, important oxygen to be supplied and nutrient is delivered to joint,
IA waste is removed in help.Chondroitin sulfate is used cooperatively with D- aminoglucose sulfates, with analgesic, promotes cartilage
Effect of regeneration, can improve joint prob from basic.Pad effect is provided, the impact and friction during action is relaxed, can be by water
Divide suction proteoglycan intramolecular, make cartilage thickening, and increase IA synovia amount.
Calcium can be divided into two kinds of mechanism of active transport and Passive intake in the absorption of small intestine.First, in duodenum and jejunum
Upper end (upper part of small intestine) absorbs calcium in saturable active transport mode, and this process need to be produced by vitamin D by its molecule
Thing --- calbindin (CaBP) is adjusted；Then it is main with undersaturated diffusion in ileum and distal small intestine (small intestine bottom)
Mode of movement Passive intake.With regard to small intestine generally speaking, the absorption area of bottom is much larger than top, and the uptake of small intestine bottom calcium is accounted for
The 75%~80% of gross absorption.Under normal physiological status, the region of small intestine middle and lower part Passive intake is influence calcium balance
Major part, it is only necessary to promote absorption of the distal small intestine to calcium.The calcium taken in food, in stomach and the acid condition of small intestine
Under, it can be in good dissolved state, but under the weakly alkaline environment of pH7 in the middle part of small intestine~8, calcium ion easily forms insoluble salt
Precipitation, hinders the diffusion transport of calcium, causes absorptivity to decline.CPP is due to the compatibility to divalent metal, energy
With calcium in this weakly alkaline environment formation soluble complexes of small intestine, the commutative combination of this moderate strength can effectively be prevented
Only the formation of calcium phosphate precipitation and increase the concentration of solubility calcium, and without prejudice to and intestinal mucosa are exchanged, so as to promote enteral calcium
Absorption.Simultaneously as CPP molecule carries the electric charge of high concentration, allow them to resist entering for enteral digestive ferment
One one-step hydrolysis, this property turns into the premise that it plays a role in enteron aisle.Therefore CPP, vitamin D are selected
The composition component provided with calcium agent as the present invention is administered simultaneously, it is possible to increase to the absorptivity of calcium, pre- preventing bone rarefaction.
Compared with prior art, its detailed description is as follows by the application：
Tibetan medicinal composition and its preparation of the pre- preventing bone rarefaction containing highland barley monascus that the present invention is provided, raw material include：
Highland barley monascus, Yak Bone, Rhizoma Drynariae extract, Shorthorned Epimedium P.E, calcium carbonate, D- Glucosamine sulfate potassium chlorides, sulfuric acid are soft
Ossein, CPP, vitamin D.Nine kinds of components play a part of pre- preventing bone rarefaction by multipath, highland barley monascus,
Rhizoma Drynariae extract, Shorthorned Epimedium P.E collective effect adjustable bone cell growth, propagation and differentiation, promote the increasing of Gegenbaur's cell
Grow, break up and calcification maturation, suppress osteoclastic bone resorption, bone density can be increased, the microstructure of bone is repaired, prevent sclerotin
It is loose；D- Glucosamine sulfate potassium chlorides and chondroitin sulfate improve joint prob for compounding, coordinate pre- preventing bone rarefaction；Carbonic acid
Calcium, CPP and vitamin D are the pre- preventing bone rarefactions in the form of replenishing the calcium and promote calcium uptake, and are matched somebody with somebody by component
Than pre- preventing bone rarefaction remarkable result.Meanwhile, human body is had no toxic side effect.
Embodiment
In order that those skilled in the art more fully understands technical scheme, with reference to specific embodiment pair
The present invention is described in further detail.
It is in parts by weight, described to hide the invention provides a kind of Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus
Drug composition raw material includes：15~45 parts of highland barley monascus, 10~30 parts of Yak Bone, 10~20 parts of Rhizoma Drynariae extract, barrenwort
5~15 parts of extract, 1~10 part of calcium agent, 1~10 part of D- Glucosamine sulfate potassium chlorides, 1~10 part of chondroitin sulfate, junket egg
White 1~10 part of phosphoeptide, 1~10 part of vitamin D.
According to the present invention, it is preferred that in parts by weight, the Tibetan medicinal composition raw material includes：25~40 parts of highland barley monascus,
15~25 parts of Yak Bone, 12~18 parts of Rhizoma Drynariae extract, 7~13 parts of Shorthorned Epimedium P.E, 2~8 parts of calcium agent, D- aminoglucoses
Sugared 2~8 parts of potassium sulfate salt, 2~8 parts of chondroitin sulfate, 2~8 parts of CPP, 2~8 parts of vitamin D.It is furthermore preferred that
In parts by weight, the Tibetan medicinal composition raw material includes：It is 30 parts of highland barley monascus, 20 parts of Yak Bone, 15 parts of Rhizoma Drynariae extract, excessive
10 parts of sheep leaves of pulse plants extract, 5 parts of calcium agent, 5 parts of D- Glucosamine sulfate potassium chlorides, 5 parts of chondroitin sulfate, 5 parts of CPP,
5 parts of vitamin D.It is preferred that, the calcium agent is calcium carbonate, calcium citrate, calcium phosphate.It is furthermore preferred that the calcium agent calcium carbonate.
Present invention also offers a kind of Tibetan medicinal composition preparation of pre- preventing bone rarefaction containing highland barley monascus, the Tibetan medicine combination
Thing preparation is made up of above-mentioned Tibetan medicinal composition and pharmaceutically acceptable auxiliary material.
According to the present invention, the preparation formulation be solution, syrup, granule, capsule, powder, pill, tablet,
Freeze dried powder, patch, gel, film, vina or extract.It is preferred that, it is calculated in mass percent, is hidden described in the preparation
Drug composition content range is 50%~90%.It is furthermore preferred that being calculated in mass percent, Tibetan medicinal composition described in the preparation
Content range is 70%.
Present invention also offers application of the above-mentioned Tibetan medicinal composition in the health food of pre- preventing bone rarefaction.
Present invention also offers a kind of preparation method of Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus, including with
Lower step：In parts by weight, the composition material includes：15~45 parts of highland barley monascus, 10~30 parts of Yak Bone, the rhizome of davallia are carried
Take 10~20 parts of thing, 5~15 parts of Shorthorned Epimedium P.E, 1~10 part of calcium agent, 1~10 part of D- Glucosamine sulfate potassium chlorides, sulfuric acid
1~10 part of chondroitin, 1~10 part of CPP, 1~10 part of vitamin D；After the raw material is crushed, solvent extraction,
Filtrate is collected, concentration is produced.
According to the present invention, the solvent is water or ethanol.It is preferred that, the solvent is water or ethanol.It is furthermore preferred that described
Ethanol is 50~75vol% ethanol.It is preferred that, the solvent extraction temperature is 75~100 DEG C.It is preferred that, the solvent extraction
Time is 1~3h.The raw material is 1 with the solvent volume ratio：(5~10).It is 0.4 that the concentration, which is specially concentrated into density,
~0.6g/mL.
Part described in technical solution of the present invention is in gram.
Embodiment 1
The Tibetan medicinal composition of pre- preventing bone rarefaction containing highland barley monascus and preparation method thereof
Tibetan medicinal composition raw material includes：Highland barley monascus 30g, Yak Bone 20g, Rhizoma Drynariae extract 15g, Shorthorned Epimedium P.E
10g, calcium carbonate 5g, D- Glucosamine sulfate potassium chloride 5g, chondroitin sulfate 5g, CPP 5g, vitamin D 5g.
Preparation method：After above-mentioned raw materials are crushed, 90 DEG C, through solvent extraction 2.5h, are collected filtrate, take the filtrate to concentrate
It is 0.5g/mL to density, produces；The solvent is 75vol% ethanol；The raw material is 1 with the solvent volume ratio：8.
Embodiment 2
The present embodiment and the difference of embodiment 1 are：
Tibetan medicinal composition raw material includes：Highland barley monascus 15g, Yak Bone 10g, Rhizoma Drynariae extract 10g, Shorthorned Epimedium P.E
5g, calcium carbonate 1g, D- Glucosamine sulfate potassium chloride 1g, chondroitin sulfate 1g, CPP 1g, vitamine D1 g.
Embodiment 3
The present embodiment and the difference of embodiment 1 are：
Tibetan medicinal composition raw material includes：Highland barley monascus 25g, Yak Bone 15g, Rhizoma Drynariae extract 12g, Shorthorned Epimedium P.E
7g, calcium carbonate 2g, D- Glucosamine sulfate potassium chloride 2g, chondroitin sulfate 2g, CPP 2g, calciferol g.
Embodiment 4
The present embodiment and the difference of embodiment 1 are：
Tibetan medicinal composition raw material includes：Highland barley monascus 40g, Yak Bone 25g, Rhizoma Drynariae extract 18g, Shorthorned Epimedium P.E
13g, calcium carbonate 8g, D- Glucosamine sulfate potassium chloride 8g, chondroitin sulfate 8g, CPP 8g, vitamin D 8g.
Embodiment 5
The present embodiment and the difference of embodiment 1 are：
Tibetan medicinal composition raw material includes：Highland barley monascus 45g, Yak Bone 30g, Rhizoma Drynariae extract 20g, Shorthorned Epimedium P.E
15g, calcium carbonate 10g, D- Glucosamine sulfate potassium chloride 10g, chondroitin sulfate 10g, CPP 10g, vitamin
D10g。
Embodiment 6
The present embodiment and the difference of embodiment 1 are：
Tibetan medicinal composition raw material includes：Highland barley monascus 30g, Yak Bone 20g, Rhizoma Drynariae extract 15g, Shorthorned Epimedium P.E
10g, calcium citrate 5g, D- Glucosamine sulfate potassium chloride 5g, chondroitin sulfate 5g, CPP 5g, vitamin D 5g.
Embodiment 7
The present embodiment and the difference of embodiment 1 are：
Tibetan medicinal composition raw material includes：Highland barley monascus 30g, Yak Bone 20g, Rhizoma Drynariae extract 15g, Shorthorned Epimedium P.E
10g, calcium phosphate 5g, D- Glucosamine sulfate potassium chloride 5g, chondroitin sulfate 5g, CPP 5g, vitamin D 5g.
Embodiment 8
The present embodiment and the difference of embodiment 1 are：
Preparation method：After raw material described in embodiment is crushed, through 75 DEG C of solvent extraction 1h, filtrate is collected, the filtrate is taken
Density is concentrated into for 0.6g/mL, is produced；The solvent is water；The raw material is 1 with the solvent volume ratio：5.
Embodiment 9
The present embodiment and the difference of embodiment 1 are：
Preparation method：After raw material described in embodiment is crushed, through 100 DEG C of solvent extraction 3h, filtrate is collected, the filtrate is taken
Density is concentrated into for 0.4g/mL, is produced；The solvent is 50vol% ethanol；The raw material is 1 with the solvent volume ratio：
10。
Embodiment 10
Tibetan medicinal composition solution of the pre- preventing bone rarefaction containing highland barley monascus
Tibetan medicinal composition made from Example 1~9, adds customary adjuvant, mixes, conventionally, and prevention is made
Tibetan medicinal composition solution of the osteoporosis containing highland barley monascus；It is calculated in mass percent, institute in the Tibetan medicinal composition solution
It is 50% to state Tibetan medicinal composition content.
Embodiment 11
Tibetan medicinal composition syrup of the pre- preventing bone rarefaction containing highland barley monascus
Tibetan medicinal composition made from Example 1~9, adds customary adjuvant, mixes, conventionally, and prevention is made
Tibetan medicinal composition syrup of the osteoporosis containing highland barley monascus；It is calculated in mass percent, institute in the Tibetan medicinal composition syrup
It is 52% to state Tibetan medicinal composition content.
Embodiment 12
Tibetan medicinal composition granule of the pre- preventing bone rarefaction containing highland barley monascus
Tibetan medicinal composition made from Example 1~9, adds customary adjuvant, mixes, conventionally, and prevention is made
Tibetan medicinal composition granule of the osteoporosis containing highland barley monascus；It is calculated in mass percent, institute in the Tibetan medicinal composition granule
It is 55% to state Tibetan medicinal composition content.
Embodiment 13
Tibetan medicinal composition capsule of the pre- preventing bone rarefaction containing highland barley monascus
Tibetan medicinal composition made from Example 1~9, adds customary adjuvant, mixes, conventionally, and prevention is made
Tibetan medicinal composition capsule of the osteoporosis containing highland barley monascus；It is calculated in mass percent, institute in the Tibetan medicinal composition capsule
It is 60% to state Tibetan medicinal composition content.
Embodiment 13
Tibetan medicinal composition powder of the pre- preventing bone rarefaction containing highland barley monascus
Tibetan medicinal composition made from Example 1~9, adds customary adjuvant, mixes, conventionally, and prevention is made
Tibetan medicinal composition powder of the osteoporosis containing highland barley monascus；It is calculated in mass percent, is hidden described in the Tibetan medicinal composition powder
Drug composition content is 65%.
Embodiment 14
Tibetan medicinal composition pill of the pre- preventing bone rarefaction containing highland barley monascus
Tibetan medicinal composition made from Example 1~9, adds customary adjuvant, mixes, conventionally, and prevention is made
Tibetan medicinal composition pill of the osteoporosis containing highland barley monascus；It is calculated in mass percent, is hidden described in the Tibetan medicinal composition pill
Drug composition content is 68%.
Embodiment 15
Tibetan medicinal composition tablet of the pre- preventing bone rarefaction containing highland barley monascus
Tibetan medicinal composition made from Example 1~9, adds customary adjuvant, mixes, conventionally, and prevention is made
Tibetan medicinal composition tablet of the osteoporosis containing highland barley monascus；It is calculated in mass percent, is hidden described in the Tibetan medicinal composition tablet
Drug composition content is 70%.
Embodiment 15
Tibetan medicinal composition freeze dried powder of the pre- preventing bone rarefaction containing highland barley monascus
Tibetan medicinal composition made from Example 1~9, adds customary adjuvant, mixes, conventionally, and prevention is made
Tibetan medicinal composition freeze dried powder of the osteoporosis containing highland barley monascus；It is calculated in mass percent, the Tibetan medicinal composition freeze dried powder
Described in Tibetan medicinal composition content be 72%.
Embodiment 16
Tibetan medicinal composition patch of the pre- preventing bone rarefaction containing highland barley monascus
Tibetan medicinal composition made from Example 1~9, adds customary adjuvant, mixes, conventionally, and prevention is made
Tibetan medicinal composition patch of the osteoporosis containing highland barley monascus；It is calculated in mass percent, is hidden described in the Tibetan medicinal composition patch
Drug composition content is 75%.
Embodiment 17
Tibetan medicinal composition gel of the pre- preventing bone rarefaction containing highland barley monascus
Tibetan medicinal composition made from Example 1~9, adds customary adjuvant, mixes, conventionally, and prevention is made
Tibetan medicinal composition gel of the osteoporosis containing highland barley monascus；It is calculated in mass percent, institute in the Tibetan medicinal composition gel
It is 80% to state Tibetan medicinal composition content.
Embodiment 18
Tibetan medicinal composition film of the pre- preventing bone rarefaction containing highland barley monascus
Tibetan medicinal composition made from Example 1~9, adds customary adjuvant, mixes, conventionally, and prevention is made
Tibetan medicinal composition film of the osteoporosis containing highland barley monascus；It is calculated in mass percent, is hidden described in the Tibetan medicinal composition film
Drug composition content is 82%.
Embodiment 19
Tibetan medicinal composition vina of the pre- preventing bone rarefaction containing highland barley monascus
Tibetan medicinal composition made from Example 1~9, adds customary adjuvant, mixes, conventionally, and prevention is made
Tibetan medicinal composition vina of the osteoporosis containing highland barley monascus；It is calculated in mass percent, is hidden described in the Tibetan medicinal composition vina
Drug composition content is 85%.
Embodiment 20
Tibetan medicinal composition extract of the pre- preventing bone rarefaction containing highland barley monascus
Tibetan medicinal composition made from Example 1~9, adds customary adjuvant, mixes, conventionally, and prevention is made
Tibetan medicinal composition extract of the osteoporosis containing highland barley monascus；It is calculated in mass percent, institute in the Tibetan medicinal composition extract
It is 90% to state Tibetan medicinal composition content.
Embodiment 21
Physical and chemical index detection is carried out to Tibetan medicinal composition prepared by embodiment 1,1 is the results are shown in Table.
Table 1
| Project | Index |
| Lead (in terms of pb) mg/kg≤ | 1.5 |
| Arsenic (in terms of As) mg/kg≤ | 1.0 |
| Total mercury (in terms of Hg) mg/kg≤ | 0.3 |
Testing result shows, in Chinese medicine composition made from the preparation method provided by the present invention, reduces lead, total
The content of the heavy metals such as arsenic, total mercury, the content of lead is controlled within 1.5mg/kg, the content control of total arsenic 1.0mg/kg with
Interior, the content of total mercury is controlled within 0.3mg/kg, and human body is had no toxic side effect.
Embodiment 22
Acute toxicity maximum resistance test
It is maximum that according to embodiments of the present invention 10~20 Tibetan medicinal composition preparations prepared carry out acute toxicity in animal body
Resistance test, the day maximal tolerance dose that mouse is administered is 420 times of adult's consumption per day, does not observe the present invention under this dosage
The toxic reaction of the preparation prepared.
Embodiment 23
Mouse model experiment
Modelling and administration
Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus that embodiment 1~9 is prepared, add water mixing respectively,
Tibetan medicinal composition solution of the pre- preventing bone rarefaction containing highland barley monascus is made；It is calculated in mass percent, the Tibetan medicinal composition is molten
Tibetan medicinal composition content described in liquor is 50%；Numbering A-I respectively.
Rat is randomly divided into 10 groups, every group 10.In addition to blank control group, other 9 groups of rats by intraperitoneal injection 50mg/kgBW
Nembutal sodium solution is anaesthetized, and middle lower abdomen unhairing is carried out after partly sterilised with the tincture of iodine and alcohol, and it is left to be 1cm along stomach wall median line
Right cut mouthful implements castration operation to rat, extracts bilateral ovaries.
After female rats excisions ovary March, decrease in estrogen, bone conversion accelerates, and bone information is more than bon e formation, bone weight
Build it is unbalance cause bone amount to reduce, trabecular bone structure change, bone biomechanical property be deteriorated, bone fragility increase and easily fracture,
Form obvious osteoporosis status.
Daily oral gavage gives each experimental group Tibetan medicinal composition, and blank control group, model group give distilled water, experiment week
12 weeks phases.
The experiment recorded according to embodiment carries out femur weight, the detection of femur total calcium content, the results are shown in Table 2.
The rat femur weight of table 2 and calcium content of bone
Compared with blank group, model group unit femur calcium content is significantly reduced, illustrate potential model modeling success；With blank
Group compares, and the present invention provides pre- Tibetan medicinal composition of the preventing bone rarefaction containing highland barley monascus as the unit femur calcium content of experimental group
Significantly rise.
Embodiment 24
Long-term clinical trials
First, subjects
1st, with reference to " Chinese's osteoporosis suggestion diagnostic criteria (the second original text) ", it is necessary to possess overall pain, more with waist
Back pain is obvious, and microtrauma can cause fracture, or scheuermann kyphosis deformity, or bone density (BMD) to reduce more than 2 standard deviations
Person.
2nd, inclusive criteria：1) there are typical OP clinical symptoms, meet OP diagnostic criteria；2) age is between 45-70 Sui
Person；3) voluntarily as study subject, informed consent form, and energy reception test pharmaceutical dosage form are signed, it is ensured that complete course for the treatment of person.
3rd, exclusion standard：
1) Secondary cases such as hyperparathyroidism, malacosteon, rheumatoid arthritis, Huppert's disease sclerotin dredges
Loose disease and other serious complication persons；
2) substantially bow-backed deformity, disabled and disability person is presented；
3) serious cardiovascular and cerebrovascular diseases, liver, kidney, lung and hemopoietic system primary disease person are suffered from；4. within the course for the treatment of observation period,
Due to a variety of causes, such as go out, residence migration can not obtain follow-up person on request；5. to this drug allergy person or to a variety of
Drug allergy person；
4) mental disease or patients with Alzheimer disease；
5) fail during testing by regulation medication or the person of dropping by the wayside.
Patient 50 is chosen according to above-mentioned standard, wherein man 25, female 25, average age 50 years old.
2nd, treatment method
1st, medicament and dosage：
Medicament：Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus that Example 1 is prepared, addition is conventional auxiliary
Material, is mixed, conventionally, and Tibetan medicinal composition tablet of the pre- preventing bone rarefaction containing highland barley monascus is made；With mass percent
Tibetan medicinal composition content is 50% in meter, Tibetan medicinal composition tablet；
Dosage：Twice a day, each one.It was a course for the treatment of with 30 days, is carried out continuously two courses for the treatment of.
2nd, criterion of therapeutical effect：According to Zheng Xiao cornel new Chinese medicines guideline of clinical investigations (tentative) (s) Beijing：Chinese Medicine
Science Press, 2002；357-358. to formulate criterion of therapeutical effect.It is effective：Pain is wholly absent, and BMD, which is checked, shows bone density
Increase；Effectively：Pain is relieved, and BMD, which is checked, has no that bone density declines；It is invalid：Compared with before treatment, each side nothing changes
It is kind.
3rd, result of the test：50 patients all meet effective standard after treatment.
It the above is only the preferred embodiment of the present invention, it is noted that above-mentioned preferred embodiment is not construed as pair
The limitation of the present invention, protection scope of the present invention should be defined by claim limited range.For the art
For those of ordinary skill, without departing from the spirit and scope of the present invention, some improvements and modifications can also be made, these change
Enter and retouch and also should be regarded as protection scope of the present invention.
Claims (10)
1. a kind of Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus, it is characterised in that in parts by weight, the Tibetan medicine group
Compound raw material includes：15~45 parts of highland barley monascus, 10~30 parts of Yak Bone, 10~20 parts of Rhizoma Drynariae extract, barrenwort are extracted
5~15 parts of thing, 1~10 part of calcium agent, 1~10 part of D- Glucosamine sulfate potassium chlorides, 1~10 part of chondroitin sulfate, casein phosphorus
Sour 1~10 part of peptide, 1~10 part of vitamin D.
2. Tibetan medicinal composition according to claim 1, it is characterised in that in parts by weight, the Tibetan medicinal composition raw material
Including：25~40 parts of highland barley monascus, 15~25 parts of Yak Bone, 12~18 parts of Rhizoma Drynariae extract, Shorthorned Epimedium P.E 7~13
Part, 2~8 parts of calcium agent, 2~8 parts of D- Glucosamine sulfate potassium chlorides, 2~8 parts of chondroitin sulfate, 2~8 parts of CPP,
2~8 parts of vitamin D.
3. Tibetan medicinal composition according to claim 1, it is characterised in that in parts by weight, the Tibetan medicinal composition raw material
Including：30 parts of highland barley monascus, 20 parts of Yak Bone, 15 parts of Rhizoma Drynariae extract, 10 parts of Shorthorned Epimedium P.E, 5 parts of calcium agent, D- amino
5 parts of glucosamine sulphate sylvite, 5 parts of chondroitin sulfate, 5 parts of CPP, 5 parts of vitamin D.
4. Tibetan medicinal composition according to claim 1, it is characterised in that the calcium agent is calcium carbonate, calcium citrate, phosphoric acid
Calcium.
5. a kind of Tibetan medicinal composition preparation of pre- preventing bone rarefaction containing highland barley monascus, it is characterised in that the Tibetan medicinal composition system
Agent is made up of any one of Claims 1 to 4 Tibetan medicinal composition and pharmaceutically acceptable auxiliary material.
6. Tibetan medicinal composition preparation according to claim 5, it is characterised in that the preparation formulation is solution, syrup
Agent, granule, capsule, powder, pill, tablet, liquid drugs injection, freeze dried powder, patch, gel, film, pill, vina
Or extract.
7. according to the Tibetan medicinal composition preparation described in claim 5, it is characterised in that be calculated in mass percent, institute in the preparation
It is 50%~90% to state Tibetan medicinal composition content range.
8. application of the Tibetan medicinal composition in the health food of pre- preventing bone rarefaction according to any one of Claims 1 to 4.
9. a kind of preparation method of Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus, it is characterised in that including following step
Suddenly：In parts by weight, the composition material includes：15~45 parts of highland barley monascus, 10~30 parts of Yak Bone, Rhizoma Drynariae extract
10~20 parts, 5~15 parts of Shorthorned Epimedium P.E, 1~10 part of calcium agent, 1~10 part of D- Glucosamine sulfate potassium chlorides, chondroitin sulfate
1~10 part of element, 1~10 part of CPP, 1~10 part of vitamin D；After the raw material is crushed, solvent extraction is collected
Filtrate, concentration, produces.
10. preparation method according to claim 9, it is characterised in that the solvent is water or ethanol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710557511.7A CN107233563A (en) | 2017-07-10 | 2017-07-10 | Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus, preparation, using and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710557511.7A CN107233563A (en) | 2017-07-10 | 2017-07-10 | Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus, preparation, using and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107233563A true CN107233563A (en) | 2017-10-10 |
Family
ID=59991004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710557511.7A Pending CN107233563A (en) | 2017-07-10 | 2017-07-10 | Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus, preparation, using and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107233563A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557424A (en) * | 2004-02-09 | 2004-12-29 | 沈阳药科大学 | Chinese compound prescription for treating osteoporosis and its preparing process |
| CN101401833A (en) * | 2008-09-27 | 2009-04-08 | 深圳市一德堂医药有限公司 | Composition for preventing and/or treating osteoporosis |
| CN101537170A (en) * | 2008-03-17 | 2009-09-23 | 哈药集团制药六厂 | Compound for preventing osteoporosis and osteoarthrosis |
| CN102586119A (en) * | 2012-01-03 | 2012-07-18 | 西藏月王生物技术有限公司 | Functional monascus strain, and preparation method and application of functional highland barley monascus prepared by using functional monascus strain |
| CN102626225A (en) * | 2012-04-25 | 2012-08-08 | 广东仙乐制药有限公司 | Health food having functions of bone density increasing and joint protecting, and preparation method thereof |
| CN103721242A (en) * | 2014-01-20 | 2014-04-16 | 庞会心 | New application of pharmaceutical composition in prevention or treatment of osteoporosis |
-
2017
- 2017-07-10 CN CN201710557511.7A patent/CN107233563A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557424A (en) * | 2004-02-09 | 2004-12-29 | 沈阳药科大学 | Chinese compound prescription for treating osteoporosis and its preparing process |
| CN101537170A (en) * | 2008-03-17 | 2009-09-23 | 哈药集团制药六厂 | Compound for preventing osteoporosis and osteoarthrosis |
| CN101401833A (en) * | 2008-09-27 | 2009-04-08 | 深圳市一德堂医药有限公司 | Composition for preventing and/or treating osteoporosis |
| CN102586119A (en) * | 2012-01-03 | 2012-07-18 | 西藏月王生物技术有限公司 | Functional monascus strain, and preparation method and application of functional highland barley monascus prepared by using functional monascus strain |
| CN102626225A (en) * | 2012-04-25 | 2012-08-08 | 广东仙乐制药有限公司 | Health food having functions of bone density increasing and joint protecting, and preparation method thereof |
| CN103721242A (en) * | 2014-01-20 | 2014-04-16 | 庞会心 | New application of pharmaceutical composition in prevention or treatment of osteoporosis |
Non-Patent Citations (4)
| Title |
|---|
| 余元勋: "《中国分子骨质疏松症学》", 30 April 2016, 《安徽科学技术出版社》 * |
| 谭友莉 等: "青稞红曲的质量标准研究", 《世界科学技术-中医药现代化》 * |
| 钱之玉: "《药理学》", 31 August 2015, 中国医药科技出版社 * |
| 青稞红曲: "青稞红曲", 《青稞红曲》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106135890A (en) | A kind of alimentation composition contributing to bony articulation health | |
| CN106235311A (en) | A kind of compositions promoting skeletal system health and application thereof | |
| CN101695382A (en) | Calcium supplementing preparation with functions of improving bones and joints | |
| CN101590184A (en) | A kind of Chinese medicine composition that is used for the treatment of gout and preparation method thereof | |
| CN101590168A (en) | A kind of Chinese medicine composition that is used for the treatment of gout and preparation method thereof | |
| WO2006133055A2 (en) | Method and composition for increasing the alkalinity of the body | |
| RU2309751C1 (en) | Method for treating the disorders of mineral metabolism at arthritis, or osteochondrosis, or rickets, or arthrosis, or osteoporosis | |
| CN101268836B (en) | Nutrition high calcium medicinal granule and preparing technique | |
| CN101129956B (en) | Traditional Chinese medicine for treating rickets | |
| CN107233563A (en) | Tibetan medicinal composition of the pre- preventing bone rarefaction containing highland barley monascus, preparation, using and preparation method thereof | |
| CN1833658A (en) | Medicine for treatment of cardio-cerebral blood vessel diseases and diabetes, and its prepn. method | |
| CN105770850A (en) | Health care product for adjuvant treatment of osteoarticular diseases and preparation method of health care product | |
| WO2019134534A1 (en) | Use of e-10-hydroxyl-2-decylenic acid in preparation of medicine or health care product for preventing and treating osteoporosis | |
| CN108719998A (en) | A kind of oral diet supplement medicament for treating osteoarthritis | |
| CN105982911A (en) | Preparation method of high-viscoelasticity injection composed of glucosamine and sodium hyaluronate | |
| US8337910B2 (en) | Herbal formulation for the treatment of bone fractures and osseous defects | |
| CN101590169A (en) | A kind of Chinese medicine composition that is used for the treatment of gout and preparation method thereof | |
| CN105267949A (en) | Medicine prescription for degenerative arthritis and osteoporosis and tablet preparation method thereof | |
| CN102626420B (en) | Mixed preparation containing strontium, calcium and vitamin D | |
| CN101703764B (en) | Medicament for treating degenerative osteopathy and preparation method thereof | |
| JPH10114665A (en) | Improver for aqueous body fluid and composition for oral administration comprising the same | |
| CN102000110A (en) | Composition used for preventing or treating bone and joint diseases and preparation method thereof | |
| CN101590166A (en) | A kind of Chinese medicine composition that is used for the treatment of gout and preparation method thereof | |
| CN109806245A (en) | A kind of drug to be eased pain as raw material preparation with treatment of arthritis function using cedrol | |
| CN102948760A (en) | Health-care product for increasing bone density and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171010 |